Literature DB >> 15061133

N-myc transcription molecule and oncoprotein.

Wayne D Thomas1, Anna Raif, Loen Hansford, Glenn Marshall.   

Abstract

N-myc has emerged as a member of a transcriptional regulatory network which impinges directly on the machinery of cell growth and proliferation. Critical during neural crest embryogenesis, N-myc is rapidly down-regulated as tissues become terminally differentiated and growth-arrested. The involvement of N-myc in these fundamental cellular processes necessitates an intricate strategy for its regulation, which is still being elucidated. Deregulated N-myc over-expression has clear transforming ability in vitro and in vivo. The transcriptional target genes responsible for this activity are beginning to be unravelled.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15061133     DOI: 10.1016/s1357-2725(03)00254-1

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  4 in total

1.  New Treatments for Rhabdomyosarcoma: the Importance of Target Practice.

Authors:  Frederic G Barr
Journal:  Clin Cancer Res       Date:  2011-12-13       Impact factor: 12.531

2.  Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification.

Authors:  Loen M Hansford; Wayne D Thomas; Joanna M Keating; Catherine A Burkhart; Anne E Peaston; Murray D Norris; Michelle Haber; Patricia J Armati; William A Weiss; Glenn M Marshall
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-16       Impact factor: 11.205

3.  Ciliary neurotrophic factor reduces the proliferation and promotes the differentiation of TH- MYCN transformed sympathoadrenal progenitors.

Authors:  John DeWitt; Anthony Pappas; Rae Nishi
Journal:  Dev Neurosci       Date:  2014-08-20       Impact factor: 2.984

4.  CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.

Authors:  X Zhao; D Li; J Pu; H Mei; D Yang; X Xiang; H Qu; K Huang; L Zheng; Q Tong
Journal:  Oncogene       Date:  2015-11-09       Impact factor: 9.867

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.